SITC 2017 Abstract Titles – Mechanisms of Efficacy or Toxicity

To search for abstract content based on keywords, select CTRL+F on your keyboard (or Command+F if you're using a Mac) and type a keyword to search for abstracts related to that keyword.







A syngeneic mouse model of CAR-T mediated toxicity and neuroinflammation

Eric Chadwick1, Alyssa Noll1, Yue Jiang1, Ronald Hause1, Rafael Ponce1, Hyam Levitsky1, Ruth Salmon1

1Juno Therapeutics, Seattle, WA, USA

Inflammation | Immune toxicity | CAR T cells | Gene expression | Leukemia/Lymphoma


Optimizing anti-OX40 mediated immunotherapy: preclinical exploration of the relationship between antitumor activity and isotype choice, ligand blocking capacity, dose and schedule

Chan Gao1, John Engelhardt2, Gennaro Dito1, Susan Glick1, Megan Raymond1, Marie-Claude Gaudreau1, Alan Korman2, Michael Quigley1

1Bristol-Myers Squibb, Princeton, NJ, USA 2Bristol-Myers Squibb, Redwood City, CA, USA

T cell | Checkpoint blockade | Costimulation | Regulatory T cell (Treg)


Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway

Ashvin R. Jaiswal1, Todd Bartkowiak1, Casey R. Ager1, Renee Chin1, Chao-Hsien Chen1, Pratha Budhani1, Midan Ai1, Matthew J. Reilley1, Manu M. Sebastian2, David S Hong1, Michael A Curran1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2The University of Texas MD Anderson Cancer Center, Smithville, TX, USA

Costimulation | Myeloid cells | Checkpoint blockade | Immune toxicity | Cytokine | Chemokine | Immune suppression | T cell


Evaluation of surrogate endpoints for overall survival in patients treated with immunotherapies

Howard Kaufman1, Lawrence Schwartz2, William William3, Mario Sznol4, Michael del Aguila5, Craig Whittington5, Kyle Fahrbach6, Yingxin Xu6, Eric Masson7, Andrea Vergara-Silva8

1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA 2Columbia University Medical Center, New York, NY, USA 3MD Anderson Cancer Center, Houston, TX, USA 4Yale School of Medicine, New Haven, CT, USA 5Doctor Evidence, Santa Monica, CA, USA 6Evidera, Bethesda, MD, USA 7AstraZeneca, Waltham, MA, USA 8AstraZeneca, Gaithersburg, MD, USA

Checkpoint blockade | Chemotherapy | Targeted therapy


Evaluating CD38 as a Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Michelle Kinder1, Mark Mendonca1, Khaja Syed1, Melissa Parker1, Patrick Wilkinson1, Edward Thompson1, Gerald Chu1, Christopher Chiu1, Natalie Hutnick1

1Janssen Research and Development, LLC, Spring House, PA, USA

Antibody | Gene expression | MDSC | Solid tumors | Regulatory T cell (Treg) | Targeted therapy | Tumor infiltrating lymphocytes (TILs)


Cisplatin Induces Immunogenic Cell Death in Preclinical Models of Head and Neck Squamous Cell Carcinoma

So-Jin Park1, Linda Tran1, Roy Xiao1,2, Carter Van Waes1, Nicole Schmitt1,3

1NIDCD, NIH, Bethesda, MD, USA 2Cleveland Clinic Lerner College of Medicine, Bethesda, MD, USA 3Johns Hopkins University, Bethesda, MD, USA

Chemotherapy | Tumor microenvironment | Checkpoint blockade


Improving the efficacy of cancer immunotherapy: An intimate play of CD8T and NK cells

Roman Uzhachenko1, J Shawn Goodwin1, William Hofmeister2, Anil Shanker1,3

1Meharry Medical College School of Medicine, Nashville, TN, USA 2University of Tennessee Space Institute, Tullahoma, TN, USA 3Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Adoptive immunotherapy | Tumor microenvironment | Tumor evasion | Tumor infiltrating lymphocytes (TILs) | Solid tumors | NK/NK T cell | T cell


Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

Spencer Wei1, Jacob Levine2, Alexandria Cogdill1, Yang Zhao1, Nana-Ama Anang1, Miles Andrews1, Padmanee Sharma1, Jing Wang1, Jennifer Wargo1, Dana Pe'er2, James Allison1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2Sloan Kettering Institute, New York, NY, USA

T cell lineages | Systems biology | Bioinformatics | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Costimulation


The Role of Radiotherapy in Driving Anti-Tumor CD8 T Cell Responses

Lauren Zebertavage1, Alejandro Alice2, Marka Crittenden2, Michael Gough2

1Oregon Health and Science University, Portland, OR, USA 2Earle A Chiles Research Institute, Portland, OR, USA

Radiotherapy | Solid tumors | T cell | Checkpoint blockade | Vaccine